Sandeep Bhave is an Oncology physician. OpenAlex indexes 18 publications with 651 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- HISTOSONICS, INC.Program year20251 payment
- BIOPROTECT MEDICAL, INC.Program year20251 payment
- GT Medical Technologies, IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
39.5%Corticosteroid39.5%Mometasone Furoate100%Part D≥23 patientsNervous system
17.1%Gabapentinoids17.1%Gabapentin100%Part D<11 patientsCardiovascular
14.5%Antiarrhythmic14.5%Lidocaine Hcl Viscous100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab
International Journal of Radiation Oncology*Biology*Physics
2020 - Multi-Site SBRT and Sequential Pembrolizumab: Treated Metastasis Control and Immune-Related Expression Predict Outcomes
International Journal of Radiation Oncology*Biology*Physics
2019 - A Validated Radiomics T Cell Score Predicts Response to Multi-site SBRT Combined with Pembrolizumab
International Journal of Radiation Oncology*Biology*Physics
2019 - A Validated Radiomics T-cell Score Predicts Response to Multi-site SBRT Combined with Pembrolizumab
International Journal of Radiation Oncology*Biology*Physics
2019
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”